Ysios leads €2m round for Inbiomotion

Ysios acquired a majority stake in the company. Co-investors included private foundations and corporates.

The funding round will support further development and clinical trials for the company's proprietary biomarker, leading towards regulatory approval.

The investment is in line with the GP's focus on healthcare and technology and was completed through the firm's inaugural fund, BioFund I.

Both Inbiomotion and Ysios are located at the Barcelona Scientific Park, where the deal originated through personal networks.

Company
Inbiomotion is a spinout of the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine and the Catalan Institute for Research and Advanced Studies in Barcelona. The company is currently developing biomarkers for the prediction of bone metastasis from tumour biopsies in early-stage cancer patients. The biomarker aims to improve patient prognosis and clinical management.

People
Joël Jean-Mairet is a partner at Ysios and led the transaction. Dr Roger Gomis founded Inbiomotion.

Advisers
Equity - Cuatrecasas (Legal).
Company - Faus y Moliner (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain
• Ysios Capital